(Reuters) – The Pharmaceutical Group Astrazeneca announced on Monday its intention to acquire the company Esobiotec for an amount of up to a billion dollars (919.37 million euros).
The “Engineered Nanobody Lentiviral” platform (ENABL) of ESOBIOTEC is capable of genetically modifying immune cells directly inside the human body, allowing to carry out cell therapy treatments in just a few minutes while the current process takes several weeks, said Astrazeneca.
The British group will acquire the entire equity in the circulation of Esobiotec in cash which includes a first payment of $ 425 million when signing the contract. This payment will be followed by a regulation of up to $ 575 million on the basis of regulatory and development stages.
The transaction should be finalized in the second quarter of 2025 and will have no impact on the forecasts of Astrazeneca for 2025, the group said.
(Written by Chandini Monnappa in Bangalore, Pauline Foret, edited by Kate Entringer)
Copyright © 2025 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
